Table 4 Comparison among principal clinical series and our series
Study | Number of patients | Pathological responders % (TRG) | PET parameter | Correlation PET with pCR p Value | Correlation PET with DFS/OS |
|---|---|---|---|---|---|
Martoni 2011 [15] | 80 | 20% (TRG4 by Dworak) | SUVmax pre SUVmax post | Negative p = 0.05 Negative p = 0.0003 | Disease recurrence: SUVmax post >/< 5 p = 0.0003 |
Calvo 2013 [16] | 38 | 50% (TRG3–4 by Dworak) | SUVmax pre SUVmax post | Negative p = 0.12 Negative p < 0.0001 | ΔSUVmax< 4 risk of Recurrence p = 0.0007 ΔSUVmax< 4 HR = 5.73 p = 0.05 |
Park 2014 [26] | 88 | 19.3% (TRG1 by Mandard) | SUVmax pre SUVmax post MTV pre MTV post | NS p < 0.001 p = 0.029 p < 0.0001 | NA |
Dos Anjos 2016 [28] | 90 | 22.2% (TRG NA) | ΔSUVmax (40%) ΔMTV (40%) ΔTLG (40%) | p < 0.0001 p = 0.005 p = 0.03 | NA |
Janssen 2012 [30] | 26 20 | 42.3%(TRG1–2 by Mandard) 20% (TRG1–2 by Mandard) | RI SUVmax | 48% SUVmax: Spec 100% Sens 64% Spec 93% Sens 83% | NA |
Chennupati 2012 [33] | 35 | 40% (TRG 0–1 by Ryan) | SUVmax pre MTV pre SUVmax post MTV post ΔSUVmax ΔMTV | NS NS NS NS NS NS | NA |
Bang 2016 [34] | 74 | 23% (TRG 0–1 by AJCC) | SUVmax pre SUVpeak pre SUVmean pre + 2 SDs | NS NS negative p = 0.0045 | 3-years DFS NS 3-years DFS NS 3-years DFS p = 0.01 |
Leccisotti 2015 [36] | 126 | 24.6% (TRG1 by Mandard) | Early RI SUVmax Late RI SUVmax | Cut-off 61% p < 0.001 cut-off not found | 10.3% local recurrences 4.8% deaths |
Our series | 100 | 16% (TRG1 by Mandard) 31% (TRG1–2 by Mandard) | SUVmax pre SUVmean pre MTV pre TLG pre SUVmax pre SUVmean pre MTV pre TLG pre | NS NS NS NS NS NS p = 0.01 NS | 4-years DFS NS 4-years OS NS |